Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): October 4, 2017 (September 29, 2017)

 

CHAMPIONS ONCOLOGY, INC.

 

(Exact name of registrant as specified in its charter)

 

Delaware		001-11504		52-1401755
(State or Other Jurisdiction		(Commission File Number)		(IRS Employer
of Incorporation)				Identification No.)

 

1 University Plaza, Suite 307, Hackensack, New Jersey 07601

(Address of Principal Executive Offices)

 

Registrant’s telephone number, including area code: [phone]

 

N/A

(Former Name or Former Address if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

	¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

	¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

	¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

	¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

---

INFORMATION TO BE INCLUDED IN THE REPORT

 

	Item 8.01.	Other Events

 

As previously reported on Form 8-K as filed by Champions Oncology, Inc. (the "Company") with the Securities and Exchange Commission ("SEC") on April 28, 2017, the Company received written notice from the Nasdaq Stock Market ("NASDAQ") on April 24, 2017 indicating that the Company had failed to maintain a minimum market value of listed securities of $35,000,000 over the previous 30 consecutive business days as required by NASDAQ Listing Rule 550(b)(2).

On September 29, 2017, the Company received written confirmation of regained compliance with NASDAQ Listing Rule 5550(b)(2) after it was determined that from the period of September 15 to 28, 2017, the Company's market value had been $35,000,000 or greater. Accordingly, the Company has regained compliance and this matter is now closed..

---

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

		CHAMPIONS ONCOLOGY, INC.
		(Registrant)
Date: October 4, 2017	By:	/s/ David Miller
		David Miller
		Chief Financial Officer